Phaseline

Targets › FPN1

FPN1 (Ferroportin): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Metabolic and endocrine; next expected readout Apr 2028.

Transports Fe(2+) from the inside of a cell to the outside of the cell, playing a key role for maintaining systemic iron homeostasis. Transports iron from intestinal, splenic, hepatic cells, macrophages and erythrocytes into the blood to provide iron to other tissues (By similarity). (UniProt, Q9NP59)

Open in Phaseline: the race on FPN1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
CSL BehringVamifeport
Ferroportin stabilizer
FPN1Phase 2Homeostatic Iron Regulator Gene-related Hereditary HemochromatosisApr 2028

Conditions

Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis (1)

Modalities

small molecule (1)

Companies

CSL Behring (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.